Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Multicenter, Open-Label, Multiple-Dose Study of DS-8201a to Assess the Effect on the QT Interval, and Pharmacokinetics in Subjects with HER2-Expressing Metastatic and/or Unresectable Breast Cancer

X
Trial Profile

Phase 1, Multicenter, Open-Label, Multiple-Dose Study of DS-8201a to Assess the Effect on the QT Interval, and Pharmacokinetics in Subjects with HER2-Expressing Metastatic and/or Unresectable Breast Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 27 Sep 2022 Results evaluating effects of trastuzumab deruxtecan on QT/QTc interval and its pharmacokinetics,published in the Clinical Pharmacology and Therapeutics
    • 17 May 2021 Status changed from active, no longer recruiting to completed.
    • 17 May 2021 Data for characterizing T-DXd exposure-response relationships with respect to key efficacy and safety endpoints was used from from (J101 [NCT02564900], J102 [NCT03366428], A103 [NCT03368196 & A104 [NCT03383692]) and a phase 2 study (DESTINY-Breast 01 [U201; NCT03248492) published in the Clinical Pharmacology and Therapeutics.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top